Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Trial Profile

A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Gemcitabine (Primary) ; MSB 0011359C (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2018 Status changed from recruiting to suspended as the study is undergoing sponsor audit
    • 17 May 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 23 May 2018.
    • 26 Apr 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Apr 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top